Pentacyclic triterpenes: New tools to fight metabolic syndrome

Background: Metabolic syndrome is a combination of dysregulated cardiometabolic risk factors characterized by dyslipidemia, impaired glucose tolerance, insulin resistance, inflammation, obesity as well as hypertension. These factors are tied to the increased risk for type-II diabetes and cardiovascular diseases including myocardial infarction in patients with metabolic syndrome. Purpose: To review the proposed molecular mechanisms of pentacyclic triterpenes for their potential use in the metabolic syndrome. Methods: PubMed, Science Direct, and Google Scholar database were searched from commencement to April 2018. Following keywords were searched in the databases with varying combinations: metabolic syndrome, pentacyclic triterpenes, transcription factors, protein kinase, lipogenesis, adipogenesis, lipolysis, fatty acids, gluconeogenesis, cardiovascular, mitochondria, oxidative stress, pancreas, hepatic cells, skeletal muscle, 3T3-L1, C2C12, obesity, inflammation, insulin resistance, glucose uptake, clinical studies and bioavailability. Results: Pentacyclic triterpenes, such as asiatic acid, ursolic acid, oleanolic acid, 18 beta-glycyrrhetinic acid, a, beta-amyrin, celastrol, carbenoxolone, corosolic acid, maslinic acid, bardoxolone methyl and lupeol downregulate several metabolic syndrome components by regulating transcription factors, protein kinases and enzyme involved in the adipogenesis, lipolysis, fatty acid oxidation, insulin resistance, mitochondria biogenesis, gluconeogenesis, oxidative stress and inflammation. Conclusion: In vitro and in vivo studies suggests that pentacyclic triterpenes effectively downregulate various factors related to metabolic syndrome. These phytochemicals may serve as promising candidates for clinical trials for the management of metabolic syndrome.